Loading...
•
Mar 31, 2022
Ocular Therapeutix Q1 2022 Earnings Report
Ocular Therapeutix reported first quarter 2022 financial results, with DEXTENZA® net product revenue reaching $12.5 million, an 87% year-over-year increase.
Key Takeaways
Ocular Therapeutix reported an 81% increase in total net revenue, reaching $13.2 million for the first quarter of 2022. DEXTENZA® net product revenue increased by 87% year-over-year, totaling $12.5 million. The company's pipeline progressed, with the completion of enrollment in the U.S. Phase 1 clinical trial for OTX-TKI and the commencement of dosing in the Phase 2 clinical trial for OTX-TIC.
Net revenue reached $13.2 million, an 81% increase year-over-year.
DEXTENZA net product revenue was $12.5 million, an 87% increase year-over-year.
Collaboration revenue was $0.7 million from the licensing agreement with AffaMed.
The company believes that existing cash and cash equivalents are sufficient to enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023.
Revenue by Segment
Forward Guidance
The company is guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 to $60 million, Representing Annual Growth of Approximately 26% to 38%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...